# PAPMET (SWOG S1500)

Source: https://onco.cc/trials/papmet/  
OnCo record `papmet` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PAPMET was the first randomised trial dedicated to papillary kidney cancer; cabozantinib held the disease back for longer than sunitinib, the previous default, while two more selective MET inhibitors did not.

## Summary

Papillary renal cell carcinoma had been treated with drugs developed for clear cell disease. PAPMET, a SWOG-led randomised phase 2 trial, assigned 152 patients with metastatic papillary renal cell carcinoma, untreated or after one prior therapy, to sunitinib or to one of three MET-directed inhibitors: cabozantinib, crizotinib or savolitinib. The primary endpoint was progression-free survival against sunitinib.

The crizotinib and savolitinib arms were closed early for futility. Cabozantinib lengthened progression-free survival and produced more responses than sunitinib, and became the preferred single agent for papillary disease in guidelines, later joined by immunotherapy combinations tested in single-arm studies.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-17
- Also known as: PAPMET; S1500; SWOG S1500
- Tags: subtype-trials
- Registry id: NCT02761057
- Phase: 2
- Setting: Metastatic papillary renal cell carcinoma: sunitinib against cabozantinib, crizotinib or savolitinib
- Sponsor: SWOG Cancer Research Network (National Cancer Institute)
- Enrolled: 152
- Result: Cabozantinib lengthened progression-free survival compared with sunitinib in metastatic papillary renal cell carcinoma; the crizotinib and savolitinib arms closed for futility.

## Sources

- ClinicalTrials.gov NCT02761057: https://clinicaltrials.gov/study/NCT02761057

## Connected records

- cancers: [Papillary renal cell carcinoma](https://onco.cc/cancers/papillary-rcc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Crizotinib](https://onco.cc/drugs/crizotinib/), [Savolitinib](https://onco.cc/drugs/savolitinib/), [Sunitinib](https://onco.cc/drugs/sunitinib/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)
- people: [Sumanta K. Pal](https://onco.cc/people/sumanta-pal/)
- key papers: [PAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma](https://onco.cc/key-papers/paper-papmet-pal-lancet-2021/)

---
JSON: https://onco.cc/api/v1/entities/papmet.json